MedTech News
.................... by Andrew Celentano

New ‘liver-on-a-chip’ device could make drug safety testing more reliable
Creating a drug that might help treat or cure a health condition in humans is a long, complex process. After developing a candidate drug that shows potential—a process that, in and of itself, can take decades—scientists often spend years testing the safety of new medications in cells, animals and then in humans.

Smarter tissue and organ repair thanks to next-gen hydrogel
A multidisciplinary team have built hydrogels built entirely from synthetic peptides so their properties can be precisely tailored through chemical design. By harnessing the power of collagen-inspired peptides and light-triggered chemistry, a University of Ottawa research team has engineered a customizable material with the potential to be a gamechanger for soft tissue repair, whether it’s closing a surgical incision or sealing a traumatic wound.

Thermobalancing therapy emerges as drug-free option for BPH
The key defining features of Thermobalancing therapy are its high treatment efficacy and no side effects

WashU Medicine introduces new blood test for Alzheimer’s symptom timing
Researchers analysed data from two Alzheimer’s cohorts.

Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
Medtronic (NYSE: MDT)+ announced today that it received CE mark for its ColonPRO fourth-generation software for AI-assisted colonoscopy.

Biotronik wins FDA nod for pacing lead for LBBAP
Biotronik announced today that it received FDA approval for its Solia CSP S pacing lead for left bundle branch area pacing (LBBAP).

Allurion gets FDA nod for weight loss balloon
Allurion Technologies (NYSE:ALUR) announced today that the FDA granted premarket approval (PMA) for its Allurion Gastric Balloon System.

Blood test boosts Alzheimer’s diagnosis accuracy to 94.5%, clinical study shows
A protein lurking around in the blood can help with the accurate diagnosis of Alzheimer’s disease. In a recent study, researchers from Spain investigated how blood-based biomarkers, such as a protein called p-tau217, affect both the clinical diagnosis of Alzheimer’s and neurologists’ confidence in their diagnosis.